Grant: Alliance Grants
University of Waterloo
$50,000.00
Purification of SARS-CoV-2 Virus-Like Particles (VLPs) Using a Microfluidic Technique for Downstream COVID-19 Vaccine Production_x000d_ _x000d_ _x000d_ _x000d_ _x000d_
EF 2020-21
Résumé
COVID-19 has become a pandemic primarily because there are no existing treatments. Thus, ending this world health crisis requires the rapid development of vaccines and therapeutics.
Mediphage Bioceuticals, Inc. (MBI) is producing specific DNA vaccines based on virus-like particles (VLPs). VLPs are multiprotein structures that closely resemble viruses and can elicit strong immune response. VLPs are completely safe and not infectious because they do not contain any viral genetic material. To produce SARS-CoV-2 VLPs, MBI uses insect cell culture where following the VLP formation, cells are lysed for VLPs extraction. MBI urgently requires a technique to rapidly purify the VLPs from cell lysates with high efficiency and throughput while the quality of VLPs is preserved for downstream vaccine production.
In this project, MBI and the Poudineh group at the University of Waterloo will develop such a system based on microfluidic technology. Microfluidics enables rapid, cost-effective, and high through target purification. In this project, we combine bead-based assay to capture specifically the VLPs based on their surface proteins and design and fabricate a microfluidic device that can isolate the bead-VLP complex, enabling to retrieve the VLPs. Specifically, the system combines three modules: a mixing device where the VLPs are mixed with beads coated with the capture agent; a separation module which isolates the beads from the rest of contaminating molecules; and a dissociation chamber where the VLPs are recovered.
The success of this project addresses the MBI's urgent need to purify SARS-CoV-2 VLPs where the microfluidic system will be integrated into their vaccine production line.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
553518-2020
Name nom
Poudineh, Mahla
Department département
Electrical & Computer Engineering
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Purification of SARS-CoV-2 Virus-Like Particles (VLPs) Using a Microfluidic Technique for Downstream COVID-19 Vaccine Production_x000d_
_x000d_
_x000d_
_x000d_
_x000d_
Keyword
NSERC
Application summary
COVID-19 has become a pandemic primarily because there are no existing treatments. Thus, ending this world health crisis requires the rapid development of vaccines and therapeutics.
Mediphage Bioceuticals, Inc. (MBI) is producing specific DNA vaccines based on virus-like particles (VLPs). VLPs are multiprotein structures that closely resemble viruses and can elicit strong immune response. VLPs are completely safe and not infectious because they do not contain any viral genetic material. To produce SARS-CoV-2 VLPs, MBI uses insect cell culture where following the VLP formation, cells are lysed for VLPs extraction. MBI urgently requires a technique to rapidly purify the VLPs from cell lysates with high efficiency and throughput while the quality of VLPs is preserved for downstream vaccine production.
In this project, MBI and the Poudineh group at the University of Waterloo will develop such a system based on microfluidic technology. Microfluidics enables rapid, cost-effective, and high through target purification. In this project, we combine bead-based assay to capture specifically the VLPs based on their surface proteins and design and fabricate a microfluidic device that can isolate the bead-VLP complex, enabling to retrieve the VLPs. Specifically, the system combines three modules: a mixing device where the VLPs are mixed with beads coated with the capture agent; a separation module which isolates the beads from the rest of contaminating molecules; and a dissociation chamber where the VLPs are recovered.
The success of this project addresses the MBI's urgent need to purify SARS-CoV-2 VLPs where the microfluidic system will be integrated into their vaccine production line.